Physician profile
Constance A Anton
NPI 1679656904
$1,800.52
in general payments reported to CMS, 2019-2025
22 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $121 · 2022: $191 · 2023: $128 · 2024: $305 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $321.44 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $279.26 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $244.39 | 2019-2022 | |
| Abbvie INC. | $139.25 | 2022-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $115.94 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $102.55 | 2019-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $67.11 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $65.44 | 2019-2025 | Trintellix |
| Alkermes, INC. | $60.26 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $55.01 | 2023-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.24 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $41.68 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $35.69 | 2025 | Fanapt |
| Shire North American Group INC | $34.53 | 2019 | |
| Supernus Pharmaceuticals, INC. | $29.69 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $29.50 | 2019-2024 | |
| Allergan, INC. | $26.02 | 2020 | |
| Axsome Therapeutics, INC. | $25.14 | 2023 | Auvelity |
| Tris Pharma INC | $22.87 | 2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $22.59 | 2025 | Jornay Pm |
| Indivior INC. | $21.40 | 2022 | |
| Neos Therapeutics, LP | $16.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Anton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.